Introduction
============

Schizophrenia is a hereditary, disabling mental disorder that affects ∼1% of the general population. The etiology of schizophrenia is complicated and is influenced by more than genetics alone. Other factors such as neurotransmitter imbalance, abnormal neuronal development, infection, and neuronal inflammation are also possible mechanisms ([@B100]). Schizophrenia is characterized by several major clinical symptoms such as positive symptoms (hallucinations and delusions), negative symptoms (emotional blunting, and social withdrawal), and cognitive impairments (attention, performance, and working memory). *NRG1* was one of the 108 schizophrenia-associated genes identified in 2014 ([@B97]), and it attracted much attention due to its role in regulation of neuronal migration and myelination. *NRG1* is widely distributed in the frontal cortex, midbrain, and cerebellum ([@B92]; [@B69]; [@B109]), and significantly associated with endophenotypes of schizophrenia via regulating myelination ([@B18]), neuronal migration ([@B32]), and function of neurotransmitter receptors ([@B69]; [@B34]). Nrg1 can be cleaved by the proteolytic enzyme, BACE1. The BACE1-cleaved Nrg1-ntf plays roles in brain function via activation of ErbB receptor signaling pathways ([@B71]). Since most studies have compared the total Nrg1 levels between schizophrenia and healthy controls, it is critical to know whether the specific activity of BACE1 in cleavage of Nrg1 plays an important role in schizophrenia. In this review, we provide a summary and perspective on information of BACE1 involvement in Nrg1 regulation in schizophrenia according to recent clinical and preclinical discoveries, presented in three sections: (1) Nrg1 structure and cleavage pattern by BACE1; (2) BACE1-dependent Nrg1 cleavage associated with schizophrenia in human studies; (3) Animal studies of Nrg1 and BACE1 mutations with behavioral observations.

Neuregulin-1 Structure and Cleavage Pattern by BACE1
----------------------------------------------------

The neuregulin family includes four proteins (Nrg1, Nrg2, Nrg3, and Nrg4), encoded by their respective genes, which are widely expressed in various tissues including brain, heart, and breast. In general, Nrg1 can be divided into three major isoforms from alternative splicing. Type I Nrg1 has alternative names such as acetylcholine receptor inducing activity, differentiation factor, or neuregulin. Type II Nrg1 is also called glial growth factor, while type III Nrg1 is also known as sensory and motor neuron-derived factor. There are common structures between Nrg1 isoforms, such as Ig domains, EGF domains, a transmembrane region and unequal length of intracellular domain ([@B26]). Due to alternative splicing effect, Nrg1 is also divided into type alpha and beta based on the difference between the 5th and 6th cysteine amino acid in the EGF-like domain, whereas the beta variant has higher affinity for its downstream ErbB receptors ([@B130]; [@B11]) (**Figure [1](#F1){ref-type="fig"}**).

![Neuregulin-1 isoforms and membrane location. Nrg1 has six different forms, which distinguish mainly from their N-terminal peptide. All six isoforms own an EGF-like domain and contain the Ig domain excluding type III Nrg1. There is a cysteine rich domain (CRD) embedded in the lipid bilayer in the type III Nrg1, which leaves N-terminal side tethered on the membrane. As described, the other family member Nrg2, Nrg3, Nrg4 has the similar domain anchor once membrane.](fnmol-10-00302-g001){#F1}

Nrg1-induced cellular responses are mostly mediated by binding to tyrosine kinase receptors in the ErbB family. The ErbB family includes ErbB1, ErbB2, ErbB3, and ErbB4 receptors. Nrg1-mediated ErbB2 receptor activation requires the participation of ErbB3 or ErbB4 to form heterodimers ([@B10]). ErbB3 on its own lacks tyrosine kinase activity, so the activation of ErbB3 is dependent on heterodimer formation with other ErbB receptors ([@B26]). Nrg1 performs most of its functions via binding to both ErbB3 and ErbB4, while Nrg3 can only bind to ErbB4 ([@B137]).

Both human and animal studies have shown that BACE1-cleaved Nrg1-ntf plays roles in brain function via activation of ErbB receptor signaling pathways. BACE1 cleaves type I and III Nrg1 at its position between the region of EF and ME residues and releases soluble fragments of Nrg1. BACE1, together with ADAM17 or ADAM10 which is also called TACE was involved in successive release of the EGF-like domain of NRG1 type III two membrane-bound structures, which has been generated by an initial BACE1 dependent proteolytic cleavage ([@B43]). NRG3, another substrate of BACE, was considered as a compensation for loss of NRG1 and cleaved to produce EGF-domain through juxtacrine interactions with ErbB4 receptor like NRG1-CRD on axon of neuron ([@B121]). These fragments bind to the ErbB4 receptor at its EGF-like domain, thereby activating ErbB receptors involved in Nrg1/ErbB signaling pathways that ultimately increase ERK and AKT phosphorylation, which are necessary for cell survival, synaptic development, glutamatergic transmission ([@B60]; [@B75]), and remyelination ([@B45]; [@B71]). The remain fragment of NRG1 cleavage is called NRG1-CTF, which can be further processed by γ-secretase to release the NRG1-ICD that participated to enhance synaptic plasticity for the development of cortical neurons ([@B3]; [@B19]). In addition, it is speculated that the expression of NRG1-CTF might be regulated by antipsychotic drugs, as the same effect on NRG1 precursor ([@B40]; [@B4]) (**Figure [2](#F2){ref-type="fig"}**).

![Neuregulins proteolytic cleavage pattern by BACE1. The enzymatic mapping shows that the cleavage of Nrg1 is mediated by BACE1 at between Glu-Phe and Met-Glu. Then, type I Nrg1 releases its N-terminal fragment to the extracellular space, in which the Nrg1-ntf binds to ErbB4 receptor on nearby cells. Whereas type III Nrg1 was cleave by BACE1 remaining tethered on the lipid bilayer via its hydrophobic Cys-rich domain. The second may cut may occur by either BACE1 or ADAM10/17 cleavage and release the EGF-domain that signal through ErbB4 in adjacent glial cells. Nrg3 was also cleaved by BACE1, producing the EGF-domain to activity its downstream pathway. The Nrg1-CTF was cleaved by γ-secretase in the cytosolic space, producing C-terminal peptide Nrg1-ICD that may regulate neuron development.](fnmol-10-00302-g002){#F2}

Nrg1/ErbB signaling pathways are important in the regulation of the central nervous system, particularly in regulation of neuronal migration, myelination and glutamatergic networks. For example, during cortical development, neuronal Nrg1 reacts with ErbB4 in glial cells to promote cerebral cortical neurons and cerebellar granule cell migration ([@B99]). By blocking ErbB in glial cells, both radial glia formation and neuronal migration, were impaired ([@B94]). Another important function of Nrg1/ErbB signaling is helping myelin formation. The dysfunctions of myelination have been reported in the PNS of schizophrenic patients ([@B17]; [@B108]). The activation of Nrg1/ErbB has involved both formation of myelin and development myelination via axonal signaling in Schwann cells, such as Nrg1-type III which is interacting with ErbB2 and ErbB3 ([@B7]; [@B78]). In addition, Nrg1 is required for post-injury remyelination in later adulthood ([@B107]). Some reported indicated that Nrg1 can regulate Schwann cell development to promote myelination ([@B77]; [@B81]), as well as affect oligodendrocyte proliferation or differentiation ([@B27]; [@B28]). For example, the development of oligodendrocytes was paused at the pre-oligodendroblast stage in ErbB2-null mice, which indicated that Nrg1/ErbB was an essential integrant in the final step of oligodendrocyte differentiation ([@B88]). Lastly, Nrg1/ErbB signaling can directly affect glutamatergic systems by regulating the expression and function of N-methyl-D-aspartate (NMDA) receptors with brain region specificity. For example, in the prefrontal cortex, Nrg1 may promote NMDA receptor type 1 subunit endocytosis and inhibit NMDA receptor-mediated activity in prefrontal cortical pyramidal neurons ([@B135]). Nrg1 type β significantly increased levels of NMDA receptor type 2C subunit in the cerebellum ([@B37]), while also reversing the long-term potentiation in the hippocampal CA1 region through regulation of AMPA endocytosis ([@B65]). Importantly, Nrg1 and Nrg1/ErbB signaling regulate several processes of neurodevelopment that play extremely critical roles in schizophrenia neuropathology.

*NRG3*, a paralog of *NRG1*, was also reported its risk variants associated with clinical symptoms and cognitive function ([@B53]; [@B23]). Moreover, genetic modified mice of Nrg3 also exhibit behaviors consistent with psychotic disorders ([@B41]). Nrg3 is a critical mediator in the assembly of cortical inhibitory circuits and balance of ex-inhibition, which is hypothesized as pathophysiology schizophrenia ([@B5]). As the closest NRG1 homolog, NRG2 is involved in increasing susceptibility to schizophrenia from human study through interaction with other NRG and ERBB ([@B6]). Nrg2 has also been involved in the modulation of schizophrenia-liked behaviors in animal studies ([@B133]). In addition, *in vitro* studies showed that Nrg2 plays roles in dopamine system regulation, bidirectional mediation of GABAergic synaptogenesis and maturation of glutamatergic synapse in network integration of newborn neurons ([@B84]; [@B133]). Comparing other members of NRG family, there are no direct evidence of Nrg4 linked to schizophrenia. The function of Nrg4 has been mainly reported in modulating of energy metabolism and the development of obesity-associated disorders ([@B126]; [@B50]).

Human Studies: BACE1-Dependent NRG1 Cleavage in Schizophrenia
-------------------------------------------------------------

As a member of the neuregulin family, NRG1 is a key molecule involved in normal brain development. Limited human studies on NRG1 in schizophrenia have shown that the structure and biological process of NRG1 is associated with disease susceptibility as well the clinical phenotypes. In this section, we will focus on the function of BACE1-dependent NRG1 cleavage in schizophrenia clinical studies.

### NRG1 Proteolysis in Schizophrenia

BACE1 has at least 15 well-known physiological substrates, as numerous novel substrates were identified by means of different screens ([@B62]; [@B139]). Activity of BACE1 has cell-, tissue-, and substrate-specificity. Early studies of postmortem schizophrenia brains showed no differences of BACE1 protein levels in Brodmann's area (BA) 6 compared to control subjects ([@B22]). It is suggested that only measuring BACE1 protein levels in the brain might not be sufficient to show BACE1-specific activity in cleaving NRG1 in schizophrenia. Later, the same research group reported a positive correlation between the levels of BACE1 and full-length NRG1 precursor in the BA6 brain region of healthy control group. This positive relationship between BACE1 and NRG1 was not observed in the schizophrenic group; however, a reduction of the NRG1-CTF was observed in this brain region ([@B4]). Using human postmortem brain tissue, an independent research group further found brain region-specific changes of NRG1 cleavage in schizophrenic patients with a great increase in the ratio of NRG1-NTF to full length NRG1 in the BA9 region ([@B73]). However, to our knowledge, there is no study of BACE1-dependent NRG1 cleavage activity in living patients with schizophrenia.

### Genetic Studies of *NRG1* in Schizophrenia

In contrast, the genetic studies of *NRG1* in schizophrenia have been extensively investigated. While most human genetic studies indicated that variants of *NRG1* might increase risk to psychiatric disorders including schizophrenia, there are still reports from various studies with controversial results.

*NRG1* was discovered as a prime candidate gene for schizophrenia by [@B110] who used Systematic linkage disequilibrium (LD) mapping of 8p12--21 in an Icelandic study. Since then, other reports from different countries have been published, such as studies from Japan ([@B30]), China ([@B134]), Scotland ([@B114]), India ([@B63]), Italy ([@B106]), Denmark ([@B48]), Pakistan ([@B82]), Finland ([@B118]), and Sweden ([@B1]). However, different haplotypes of NRG1 were found from various studies. For instance, in the Icelandic population, SNP haplotype in the 5′ region of *NRG1* (HAP~ICE~: SNP8NRG221533, SNP8NRG241930, SNP8NRG243177) was identified with linkage of schizophrenia risk ([@B110]), while in the Scottish population, a significant association between *NRG1* (HAP~ICE~) and schizophrenia was detected by PCR ([@B109]). In Japan, researchers failed to replicate the association between *NRG1* and schizophrenia in a large Japanese population, while no association between *NRG1* and schizophrenia was also reported in a large Danish sample ([@B48]; [@B47]). In addition, a novel haplotype of the *NRG1* gene was found to confer risk of schizophrenia susceptibility in Chinese Han, but not in the Icelandic/Scottish population ([@B67]). This suggests that stratification and phenotypic heterogeneity may have constrained detection of genetic associations. Other variations or haplotypes located in *NRG1* were also associated with schizophrenia using different SNPs tagging, analysis methods, sample size, and populations. Using association analysis method, one study showed variants in *NRG1* (rs2919381) and *ERBB4* might contribute to susceptibility to schizophrenia in Japanese population ([@B104]). Evidence for *NRG3* (rs1937970 and rs677221) as a susceptibility gene for schizophrenia was identified in Chinese Han population ([@B129]). Using LD method, the haplotype 221121 of *NRG1* and its six SNPs were associated to schizophrenia in Indian population ([@B63]). In a study of Northern Swedish Isolated Population, five SNPs located in the second intron of *NRG1* were found with schizophrenia association also by LD method ([@B1]). Variants of NRG1 can be detected genetic association with schizophrenia in different periods and features of patients, which can further confirm these risks to disease.

### *NRG1* and Schizophrenia Clinical Categories

Schizophrenia symptoms are typically classified under four broad categories: positive symptoms, negative symptoms, disorganization, and cognitive dysfunction ([@B119]). *NRG1* is considered as a risk gene for schizophrenia, and variants of it are associated with schizophrenia clinical symptoms. [@B2] divided schizophrenic patients into two groups based on their chronic idiopathic negative symptoms as deficit group (negative symptoms) and non-deficit group by the Schedule for the Deficit Syndrome ([@B15]). They found *NRG1* (SNP8NRG221533) was related to the non-deficit schizophrenia subtype only in Caucasian population ([@B2]). Later, a study tested three SNPs (SNP8NRG 221132, SNP8NRG241930, and SNP8NRG 243177) in Hungarian population and found only SNP8NRG241930 was related to cognitive and hostility factors by PANSS in non-deficit schizophrenia ([@B91]). Another case-control study in Caucasian population showed several haplotypic variants of *NRG1* (SNP8NRG221533 SNP8NRG241930 SNP8NRG243177 MS478B14-848 MS420M9-1395) had "protective" effects on age of onset and positive symptoms of schizophrenia ([@B87]), which is consistent with the findings in other investigations ([@B57]; [@B1]). Recently, in a study of Iranian population, [@B136] found the G allele of rs2439272 might be significant association with negative symptoms especially in male participants and increased risk of developing schizophrenia.

### *NRG1* and Neurophysiological Endophenotypes of Schizophrenia

Endophenotypes are thought to be more stable and homogenous than clinical syndromes. Neurophysiological endophenotypes of schizophrenia are characterized by a series of biological and behavioral traits, such as changes in cognitive function, PPI, EMT, ERP and neuroimaging ([@B8]). For example, deficits of the inhibition function in patients with schizophrenia were suggested by many studies ([@B117]). The impaired inhibition function can be expressed as changes of PPI, ASEM, SPEM, P50 auditory evoked potential suppression, P300 event-related brain potential, and more. Here, we will discuss the relationship between *NRG1* gene and a few specific endophenotypes of schizophrenia.

#### *NRG1* and PPI

Pre-pulse inhibition is a neurological phenomenon that has been widely used for detecting inhibitory sensory motor gating of the startle reflex, and it is recognized as one of the schizophrenic endophenotypes ([@B13]; [@B64]). There have been several clinical studies that suggest a relationship between *NRG1* gene and PPI. One study demonstrated the lowest level of PPI in Caucasians and African Americans schizophrenia subjects who also carried the homozygous A allele (*NRG1* rs3924999) ([@B42]). Another study showed that carrying *NRG1* risk genotype variations (SNP8NRG241930, rs6994992, rs2439272 rs10503929 and rs3924999) was related to reduced PPI in healthy subjects ([@B95]). These reports suggest that individuals with *NRG1* phenotype might be associated with attenuation of PPI, regardless of if they are healthy populations or patients with schizophrenia. While the underlying mechanisms involving *NRG1* genotype in PPI are unknown, studies implicated that Nrg1 regulates NMDA receptors in specific brain regions that could induce PPI reduction and contribute to schizophrenia-like symptoms ([@B49]; [@B33]; [@B34]). Thus, glutamate signaling may be a potential target for the relationship between *NRG1* and PPI.

#### *NRG1* and ERP

The brain's gating function refers to the capacity to filter out duplicated or redundant stimuli ([@B29]). ERP, the measurement of brain response to a specific sensory, cognitive, or motor event, is a schizophrenic endophenotype. Using electroencephalography, several waveforms have been found to be related to ERP, such as N100, P50, and P300 ([@B35]). While P300 reflects attentive resource allocation to the relevant stimulation, P50 sensory gating reflects the filtering process to irrelevant stimulus in the early stage of brain attentive function ([@B90]; [@B122]). Studies of patients with schizophrenia demonstrated that NRG1-induced AKT phosphorylation is associated with P50 suppression observed in first-episode patients with schizophrenia. This finding suggests that the PI3K/AKT system may be involved in the impaired sensory gating observed in schizophrenia ([@B55]). In concert with this finding, a study of acoustic startle response and P50 in patients with schizophrenia showed greater S2 response amplitude and deficit of P50 suppression in patients with schizophrenia than in controls. However, no correlations between PPI and P50 suppression were found in either patients with schizophrenia or control groups ([@B111]), suggesting different mechanisms underlie specific schizophrenia endophenotypes. Regarding investigation of the relationship between *NRG1* gene and ERP in schizophrenia, a study found a significant linkage between SNP8NRG221533 and P300 latency, showing individuals carrying more C alleles had greater P300 latency delay ([@B9]). However, there was no significant association between *NRG1* SNPs (SNP8NRG221533, SNP8NRG241930, and SNP8NRG243177) and P50 suppression observed in a large schizophrenia endophenotype study ([@B102]). A recent meta-analytic review concluded that P50 suppression, P300 amplitude, and P300 latency may serve as viable endophenotypes for schizophrenia ([@B24]). Therefore, whether *NRG1* is related to specific schizophrenic endophenotypes might need further investigations.

#### *NRG1* and eye movement deficits

Eye movement deficits, particularly in SPEM and ASEM, are important endophenotypes in patients with schizophrenia ([@B76]; [@B123]). While a number of studies demonstrated 50--80% of patients with schizophrenia have impaired SPEM compared to 8% of healthy individuals ([@B66]; [@B25]), few studies have investigated genetic association of eye movement deficits with *NRG1*. A study of *NRG1* genotypes with eye movement deficits in 113 patients with schizophrenia and 106 age-matched healthy controls found no relationship between *NRG1* genotype (SNP8NRG222662, SNP8NRG243177) and ASEM or SPEM task performance ([@B36]). Consistent with Haraldsson's study, two studies in Korea also found no associations between *NRG1* (rs35753505G, rs4623364G; rs6994992T rs3924999A) and ASEM or SPEM abnormality ([@B89]; [@B56]). However, the result in healthy subjects showed interaction between *NRG1* and eye movement deficits. One study found SNP8NRG243177 in healthy young males was related to SPEM by using the root-mean-square error method ([@B105]), while another study showed a significant effect of *NRG1* rs3924999 genotype on ASEM amplitude gain, but not to SPEM or other variables of ASEM, in 114 healthy Caucasian subjects ([@B98]), suggesting *NRG1* genotypes may affect visuospatial sensorimotor transformations in general and could be a potential mechanism underlying impaired eye movements in patients with schizophrenia.

#### *NRG1* and neuropathology

Some of the major schizophrenia pathological characters are brain atrophy ([@B39]; [@B68]), reduction of whole brain volumes ([@B31]), and abnormality in density as well as integrity in diverse brain areas ([@B12]; [@B61]; [@B112]; [@B125]). As NRG1 plays critical roles in myelination, there is an increase in an attention to the *NRG1* gene variant association with neuropathology in patients with schizophrenia.

A reduction of white matter density and integrity in the ALIC and prefrontal subgyrus in *NRG1* (SNP8NRG243177) carriers was first reported in 2008 ([@B74]), while the SNP8NRG221533 genotype of *NRG1* was reported as affecting medial frontal white matter microstructure ([@B132]). Later, studies on SNP8NRG221533 in schizophrenia showed that the *NRG1* variation was related to decreased anterior cingulum fractional anisotropy ([@B124]), lower volume of internal capsule ([@B14]), and reduced volume of left UF ([@B120]). In addition to white matter, studies also explored the effect of *NRG1* variation on gray matter volume. For example, two studies suggested that *NRG1* (rs35753505) was significantly associated with gray matter volume reduction ([@B58]; [@B113]), while another investigation found a significant association between SNP8NRG222662 (rs4623364) and reduced volume of left superior temporal gyrus cortex ([@B116]). However, whether *NRG1* genetic variations directly cause brain structural and functional changes in schizophrenia remains unclear and further studies in schizophrenic patients with neuroimaging in combination with other disease-specific biomarkers would be helpful.

In summary, human studies demonstrated that *NRG1* as a schizophrenia-linked candidate gene plays an important role in the pathological process of schizophrenia through its effect on brain function. Together, findings provide evidence to support an important role of NRG1 in neurodevelopment and susceptibility to schizophrenia (**Table [1](#T1){ref-type="table"}**).

###### 

Effect of *NRG1* on schizophrenia in human studies.

                                    Features                    Results                                                                                                                                                                                                                                                                                                                                                                                                                           Reference
  --------------------------------- --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  Protein expression in the brain   N-terminal                  The level of NRG1-NTF was increased in BA9 of schizophrenia                                                                                                                                                                                                                                                                                                                                                                       [@B73]
                                    C-terminal                  The level of NRG1-CTF was decreased in BA6 of schizophrenia                                                                                                                                                                                                                                                                                                                                                                       [@B4]
                                    Full length                 The level of full-length NRG1 was lower in BA9 of schizophrenia; No changes in BA6 of schizophrenia                                                                                                                                                                                                                                                                                                                               [@B4]; [@B73]
  Genetic association               HAP~ICE~                    SNP8NRG221533, SNP8NRG241930, SNP8NRG243177 was reported positive association in Scottish population, negative association in Japanese population, Danish population, Chinese population                                                                                                                                                                                                                                          [@B109]; [@B67]; [@B48]; [@B47]
                                    Novel haplotypes and SNPs   The haplotype 221121 (rs35753505-rs6994992-rs1354336-rs10093107-rs3924999-rs11780123) in India population; Rs7017348, rs6468061, rs7014221, rs7014410, rs17601950 in northern Swedish Isolated population; Rs2919381 in Japanese population; HAP~China~ ~1~, HAP~China~ ~2~ and HAP~China~ ~3~ in Chinese population                                                                                                              [@B67]; [@B104]; [@B1]; [@B63]
  Clinical Categories               Non-Deficit                 SNP8NRG241930 in Hungary population; SNP8NRG221533 in Caucasian population                                                                                                                                                                                                                                                                                                                                                        [@B2]; [@B91]
                                    Protective effect           SNP8NRG221533, SNP8NRG241930, SNP8NRG243177, MS478B14-848, MS420M9-1395 in Caucasian population                                                                                                                                                                                                                                                                                                                                   [@B87]
                                    Negative symptom            Rs2439272 in Iranian population                                                                                                                                                                                                                                                                                                                                                                                                   [@B136]
  Endophenotypes                    PPI                         SNP8NRG241930, rs6994992, rs2439272 rs10503929 and rs3924999 in Greek healthy males; Rs3924999 in Caucasians and African Americans                                                                                                                                                                                                                                                                                                [@B42]; [@B95]
                                    ERP                         SNP8NRG221533 in Maudsley Family                                                                                                                                                                                                                                                                                                                                                                                                  [@B9]
                                    EMT                         SNP8NRG243177 related to SPEM in healthy young males; Rs3924999 related to ASEM in healthy Caucasian                                                                                                                                                                                                                                                                                                                              [@B98]; [@B105]
                                    Neuroimaging                White matter: SNP8NRG243177 related to reduction white matter in ALIC and prefrontal subgyrus; SNP8NRG221533 related to medial frontal white matter microstructure; decreased anterior cingulum fractional anisotropy; lower volume of internal capsule; lower volume of left UF Gray matter: Rs35753505 related to gray matter volume reduction; SNP8NRG222662 related to lower volumes of left superior temporal gyrus cortex   [@B74]; [@B132]; [@B124]; [@B14]; [@B116]; [@B120]; [@B58]; [@B113]

BA, Brodmann's Area; HAP, Haplotypes; SNP, Single Nucleotide Polymorphism; PPI, Pre-Pulse Inhibition; ERP, Event-Related Potential; EMT, Eye Movement Test; SPEM, Smooth Pursuit Eye Movements; ASEM, Anti-Saccade Eye Movements; ALIC, Anterior Limb of the Internal Capsule; UF, Uncinate Fasciculus.

Preclinical Research: *Nrg1* and *BACE1* Gene Modified Animal Models
--------------------------------------------------------------------

While human studies have demonstrated that NRG1 plays critical roles in schizophrenia, preclinical research using gene knockout or mutant mice have provided some valuable evidence of association between Bace1 and Bace1-Nrg1 cleavage and schizophrenia by behavioral studies as well as pharmacological investigations.

### Mice with Mutated *Nrg1* Develop Schizophrenia-Like Behaviors

During the last decades, several types of Nrg1 transgenic mice have been developed to explore the effect of Nrg1 on behaviors, as well as the underlying mechanisms. One of which is a mouse model of heterozygous transmembrane domain Nrg1 mutant (TM-*Nrg1*^+/-^). The TM-*Nrg1*^+/-^ mice develop dysfunctional NMDA receptors in the forebrain, impaired PPI, and increased spontaneous activity that clozapine treatment was able to reverse ([@B110]). Another feature of TM-*Nrg1*^+/-^ mice was age- and brain region-related alternations of NMDA and D~2~ receptor levels which cause selective disturbance of glutamatergic and dopaminergic neurotransmission in the animals ([@B83]). A mouse model with a different mutation of *Nrg1*, a heterozygous mutation in Nrg1 immunoglobulin-like domain (Ig*-Nrg1*^+/-^), displayed schizophrenia-like behaviors, particularly suppression of open field, running wheel, and T-maze. The Ig*-Nrg1* ^+/-^ mice were more sensitive to clozapine treatment ([@B93]). Additionally, animal models of overexpression with different Nrg1 isoforms also developed schizophrenia-liked behaviors. For example, 11-month-old mice with overexpression of *Nrg1-type I* showed impaired hippocampal-dependent spatial working memory and oscillations ([@B21]), while *Nrg1-type III*-overexpressed transgenic mice developed sensorimotor gating deficits with changes in the activity of circuit projections from the vHPC to the nACC ([@B79]). Disrupted cortical-amygdala neural circuits have also been observed in similar transgenic mice, leading to altered processing of salient memories ([@B51]). A novel transgenic mouse model of overexpressed *Nrg1-type IV* (Nrg1-IV/NSE-tTA) also exhibited impaired sensorimotor function, discrimination memory, and social behaviors. The Nrg1-IV/NSE-tTA mice also expressed disrupted dendritic development, synaptic pathology, and excitatory-inhibitory imbalance in the prefrontal cortex, which may be mediated by ErbB4 and the downstream signal target, PIK3-p110δ ([@B86]). Interestingly, overexpression of secreted Nrg1 by Bace1 cleavage (Nrg1-ntf~β~) in mice was sufficient to cause schizophrenia-like phenotypes. The abnormal behaviors were Nrg1-ntf~β~-specific since turning off the Nrg1-ntf~β~ expression genetically can reverse the schizophrenia-like behaviors in the mouse model ([@B70]). Lines of evidence suggested that gain-off function mutations in Nrg1 are also risk factors for schizophrenia. According to these *Nrg1* genetic models, it is possible that dysfunction of NRG1 or NRG1/ErbB4 signaling may affect neural development and synaptic plasticity by disturbance of glutamatergic or GABAergic systems implicated in schizophrenia. We therefore summarized that schizophrenia-like behaviors are related to various *Nrg1* mutations (**Table [2](#T2){ref-type="table"}**).

###### 

The effect of *Nrgl* and *Bacel* mutation on schizophrenia-like genotypes in mice.

  Genotyping                          Feature of mice                                                         Behaviors                                                                                                        Pathology                                                                                                                                    Reference
  ----------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------
  *TM-Nrg1*^+/-^                      Transmembrane region deletion in heterozygous mice                      Impaired PPI, increased spontaneous activity                                                                     Fewer NMD A receptor level ; Disturbance glutamatergic and dopaminergic neurotransmission in different ages                                  [@B110]; [@B83]
  *Ig-Nrg1*^+/-^                      Mutation in *Nrg1* immunoglobulin-like domain in heterozygous mice      Reduced activity in open field, running wheel and T-maze, decreased latent inhibition with clozapine treatment                                                                                                                                                [@B93]
  Overexpressing *Nrg1-type I*        *Nrg1-type I* overexpressed in 11-month-old mice                        Impaired spatial working memory                                                                                  Altered hippocampal oscillatory, lower carbachol-induced epileptiform activity                                                               [@B21]
  Overexpressing *Nrg1-type III*      *Nrg1-type III* overexpressed in mice                                   Sensorimotor gating deficits; Altered salient memories                                                           Disrupted from vHPC to nACC circuit projections; Disrupted cortical-amygdala neural circuits                                                 [@B79]; [@B51]
  Overexpressing *Nrg1-I VI*NSE-tTA   Selectively *Nrg1-W* overexpressed in a neuronal specific manner mice   Impaired sensorimotor, discrimination memory and social behaviors                                                Abnormal synaptic, imbalance ex-inhibitory in PFC                                                                                            [@B86]
  Overexpressing *Nrg1-ntfβ*          N-terminal fragment overexpressed in mice                               Reduced spontaneous alternations, impaired contextual fear conditioning                                          Deceased NMDA receptors                                                                                                                      [@B70]
  *Bacel*^-/-^                        *Bace1* gene knock out mice                                             Impaired PPI, working memory and social recognition; Spontaneous hyperactivity                                   Accumulation of intact Nrgl; Impaired process of myelination; Disturbed NRGl/ErbB4 signaling pathway; Disturbed NRG1/AKT signaling pathway   [@B45], [@B44]; [@B131]; [@B96]; [@B101]

TM, Transmembrane; Ig, Immunoglobulin; vHPC, Ventral Hippocampus; nACC, Nucleus Accumbens; PFC, Prefrontal Cortex.

### Mutation of Bace1 Mice Show Schizophrenia-Like Behaviors

As a transmembrane protease, BACE1 is important for several disease-related substrates, including beta amyloid peptide production in AD and NRG1 in schizophrenia ([@B127]). In addition to BACE1 cleavage of a series of types of Nrg, including Nrg1-type I, Nrg1-type III, and Nrg3, BACE1 also cleaves the β2 subunit of voltage-gated sodium channels (Na~v~1, β2) ([@B20]) that participate in regulation of neuronal development and maintenance of normal brain function. Studies of *Bace1*^-/-^ mice showed reduction of myelination, deficits in cognitive performance, and impaired emotional activity ([@B38]; [@B45]). Moreover, the *Bace1*^-/-^ mice showed seizure-like genotype with increased expression of Na~v~1β2 in hippocampal areas, which is related to hyperactivity and elevated excitability of hippocampal neurons ([@B46]). Together, results suggest the possible relationship between BACE1 and dysfunctions of the brain such as schizophrenia, epileptic seizures, and AD.

Whether there are any specific effects of Bace1 cleavage of Nrg1 on animal behavior is still in question. Several studies of *Bace1* knockout mice have found reduction of Nrg1-type I and type III β1 levels, elevated full length Nrg1, and diminished activation of Akt in the brain ([@B131]), along with a delayed process of myelination and reduced myelin thickness ([@B45], [@B44]). This suggests that BACE1-dependent cleavage of Nrg1 may regulate myelination and myelin sheath thickness by mediating phosphorylation of Akt. As myelin and oligodendrocyte function could affect neuronal connectivity, the dysfunction of myelination may well be related to the neuropathogenesis of schizophrenia ([@B80]). Additionally, the *Bace1*^-/-^ mice treated with a glutamatergic psychostimulant showed impaired PPI, working memory, and social recognition, as well as spontaneous hyperactivity as schizophrenia-like behaviors. Decreased spine density in hippocampal pyramidal neurons was also observed in *Bace1*^-/-^ mice via NRG1/ErbB4 signal pathway regulation ([@B96]), suggesting that disturbed NRG1/ErbB4 signaling pathways in the *Bace1*^-/-^ mouse model may contribute to the pathophysiology of schizophrenia. There was a decreased DISC1 expression reported in *Nrg1*^-/-^ knockout mice, as well as in *Bace1*^-/-^ mice, which might be linked to impaired NRG1/AKT signal pathway ([@B101]). As described above, animal studies suggest that BACE1 might be involved in the pathology of schizophrenia via cleaving substrates to stimulate the downstream signal pathway (**Table [2](#T2){ref-type="table"}**).

### Nrg1 and Antipsychotic Treatment

The mechanism of antipsychotics is complicated, and includes binding with DA, 5-HT, H1, M1, and α receptors. In addition, some antipsychotics are selective for specific symptoms. For instance, risperidone works better on positive symptoms while others like aripiprazole can improve the severity of negative symptoms ([@B59]; [@B72]). While many studies focus on the effect of antipsychotic treatment on the alteration of *NRG1* gene expression in animal models, there are few human reports in this field due to the ethical issues and method limitation.

A clinical study in Chinese Han patients indicated that exposure to risperidone and quetiapine for 4 weeks could increase the NRG1 expression of peripheral blood lymphocytes of first episode schizophrenia ([@B138]). Another study showed that clozapine treatment elevated *NRG1* expression in human fetal brain aggregates, which was not yet observed in a haloperidol-treated group ([@B16]). These human studies suggest that different antipsychotic treatments may cause differential effects on expression of *NRG1*. Results from animal studies also indicate that the duration of antipsychotics also contributed to various changes of *Nrg1*. The levels of Nrg1 and ErbB4 receptors in rat prefrontal cortex and hippocampus were increased by treatment with haloperidol for 4 weeks ([@B128]), while an 8-week haloperidol treatment showed no effect on Nrg1 levels in mice ([@B103]). Furthermore, a 12-week haloperidol treatment experiment reduced the ErbB4 activation ([@B34]), as well as expression of Nrg1 and ErbB4, in the brains of mice ([@B85]). Overall, these studies suggest that not only type of antipsychotics, but also duration of antipsychotic treatment, may be a crucial factor to change *Nrg1* expression, while also considering the brain region-specific effects of antipsychotics (**Table [3](#T3){ref-type="table"}**).

###### 

Effects of antipsychotic drugs on expression of Nrg1 and ErbB4 signaling.

  ----------------------------------------------------------------------------------------------------------------------------------
                   Subjects         Drugs            Dosage                        Treatment duration   Nrg1/ErbB4       Reference
  ---------------- ---------------- ---------------- ----------------------------- -------------------- ---------------- -----------
  Human studies    PBL cells        Clozapine/\      2 μM/500 nM                   3 weeks              Up/No changes    [@B16]
                                    Haloperidol                                                                          

                   Onset patients   Risperidone/\    (533.33±71.45)mg/\            4 weeks              Up/Up            [@B138]
                                    Quetiapine       day/(544.62±63.85)\                                                 
                                                     mg/day                                                              

  Animal studies   Rat              Haloperidol/\    1 mg/kg i.p./1 mg/kg i.p./\   4 weeks              Up/Up/Down       [@B129]
                                    Risperidone/\    10 mg/kg i.p.                                                       
                                    Clozapine                                                                            

                   Monkey           Haloperidol      0.125--0.25 mg/mL/day         8 weeks              No changes       [@B103]

                   Mice             Haloperidol      2 mg/kg/day                   12 weeks             Down             [@B34]

                   Rat              Aripiprazole/\   UN                            12 weeks             Down/Down/Down   [@B85]
                                    Olanzapine/\                                                                         
                                    Haloperidol                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------

Up, Up Regulation; Down, Down Regulation; PBL, Peripheral Blood Lymphocytes; UN, Unknown.

BACE1 inhibitor as a therapeutic strategy to improve cognitive in AD has been challenging. Both safety and efficacy are questionable. *In vitro*, inhibition of BACE1 can cause adverse side effects during synaptic developmental stages ([@B52]). However, there are almost no reports on psychotic symptoms from BACE1 inhibitor clinical trials rather than improved cognitive function in AD patients ([@B54]; [@B115]). We speculated that the current available BACE1 inhibitors might be made for targeting on APP which has different cleavage site than other substrates as NRG1. Further investigations on substrate-dependent BACE1 cleavage activity are needed.

In the future, exploring the dynamic changes of BACE1-dependent NRG1 cleavage process in biological samples from schizophrenic patients would be important. It will provide new insights into how BACE1-dependent NRG1 proteolytic processing could contribute to the pathophysiology of schizophrenia, and help to discover the underlying biomarker of schizophrenia, which is essential for early diagnosis of the disorder disease and effective medical treatment.

Concluding Remarks
==================

Neuregulin, especially Nrg1, plays a major role as the psychological substrate of BACE1. Numerous lines of evidence support the hypothesis that Nrg1 can contribute to the pathophysiology of schizophrenia. Both, human and animal research, suggest that BACE1-dependent Nrg1 cleavage and NRG1/ErbB4 signaling may play specific roles in schizophrenia, as summarized in **Figure [3](#F3){ref-type="fig"}**. Several BACE1 inhibitors have entered into phase I studies, and at least one of these inhibitors has advanced to phase III human trails. Due to various BACE1 substrates, it is helpful to investigate their role and further illustrate the function of Nrg1 downstream signaling pathways in schizophrenia. It is important for understanding the biological mechanism of BACE1 together with its substrates Nrg1, and further exploring effective and specific inhibitor drugs for schizophrenia, not interfering other biological progress, which could provide possible therapeutic strategies for this psychiatry disorder. In future studies, it will be important to investigate BACE1, Nrg1-related molecular pathways, and neural circuits in endophenotypes resembling features of schizophrenia.

![Schematic of BACE1-dependent NRG1/ErbB4 signaling pathway involving in the pathogenies of schizophrenia. Neuregulins (type I, type III Nrg1 and Nrg3) are cleaved by BACE1 and release their EGF-domain into in the extracellular space, through binding the ErbB4 receptors to activate downstream signaling pathway. The NRG1/ErbB4 signaling in neurons can exert an effect on NMDA receptors interacting with PSD-95, which lead to the phosphorylation of PI3K-AKT and ERK molecules. Abnormal NRG1/ErbB4 signaling pathway may contribute to impaired myelination and synaptic function. Meanwhile, intracellular fragment of Nrg1 and ErbB4 are cut off by γ-secretase complex, producing the peptide into the nuclear to regulate neuron development.](fnmol-10-00302-g003){#F3}
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AD

:   Alzheimer Disease

AKT

:   serine/threonine kinase 1

ALIC

:   anterior limb of the internal capsule

ASEM

:   anti-saccade eye movements

BACE1

:   β-secretase

DISC1

:   disrupted in schizophrenia 1

EGF

:   epidermal growth factor

EMT

:   eye movement test

ErbB4

:   erb-b2 receptor tyrosine kinase 4

Erk

:   extracellular regulated MAP kinase

ERP

:   event-related potential

HAP

:   haplotype

Ig

:   immunoglobulin

nACC

:   nucleus accumbens

NMDA

:   N-methyl-D-aspartic acid

NRG1

:   Neuregulin-1

NRG1-CRD

:   NRG1-intracellular domain

Nrg1-ctf

:   Nrg1 C-terminal fragment

Nrg1-ntf

:   Nrg1 N-terminal fragment

NRG3

:   Neuregulin-3

PI3K

:   phosphatidylinositol-4,5-bisphosphate 3-kinase

PPI

:   pre-pulse inhibition

PSD95

:   postsynaptic density protein 95

SPEM

:   smooth pursuit eye movements

TACE

:   tumor necrosis factor-α-converting enzyme

UF

:   uncinate fasciculus

vHPC

:   ventral hippocampus
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